共 50 条
- [1] Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in RatsEUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (04) : 531 - 538Mudunuru, JennypherRen, ChenTaft, David R.Maniar, Manoj
- [2] Effect of gender on the rodent pharmacokinetics of ON 123300, a dual inhibitor of ARK5 and CDK4/6, for the treatment of cancerCANCER RESEARCH, 2018, 78 (13)Ren, ChenMudunuru, JennypherTaft, DavidManiar, Manoj
- [3] Dual CDK4/ARK5 inhibition by ON 123300 for targeting metastatic colorectal cancerABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257Reddy, M.Cosenza, StephenDivakar, SaikrishnaAkula, BalireddyMallireddigari, MuralidharReddy, Premkumar
- [4] Dual CDK4/ARK5 inhibition by ON 123300 for targeting metastatic colorectal cancerABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258Reddy, M.Cosenza, StephenDivakar, SaikrishnaAkula, BalireddyMallireddigari, MuralidharReddy, Premkumar
- [5] Dual targeting of ARK5 and CDK4 pathways with ON 123300 as a therapeutic strategy for colorectal carcinomaCANCER RESEARCH, 2016, 76Divakar, Saikrishna A.Reddy, M. V. RamanaCosenza, Stephen C.Baker, Stacey J.Purohit, VineeGunda, VenugopalSingh, Pankaj K.Reddy, E. Premkumar
- [6] Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 is effective in vitro and in vivo in Multiple MyelomaCANCER RESEARCH, 2014, 74 (19)Perumal, DeepakThirukonda, VenuJiang, ZeweiLeshchenko, Violetta V.Kuo, Pei-YuShahnaz, SamiraRubel, JenniferZhang, WeijiaCho, Hearn JayReddy, M. V. RamanaReddy, E. PremkumarParekh, Samir
- [7] Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple MyelomaCANCER RESEARCH, 2016, 76 (05) : 1225 - 1236Perumal, DeepakKuo, Pei-YuLeshchenko, Violetta V.Jiang, ZeweiDivakar, Sai Krishna AthaluriCho, Hearn JayChari, AjaiBrody, JoshuaReddy, M. V. RamanaZhang, WeijiaReddy, E. PremkumarJagannath, SundarParekh, Samir
- [8] Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancerONCOLOGY REPORTS, 2018, 40 (03) : 1592 - 1600Shi, XinanLi, HongjianShi, AnhuaYao, HongKe, KunbinDong, ChaoZhu, YingQin, YiDing, YingHe, Yan HongLiu, XuLi, LingLei, LingHai, QingshanChen, WeiLeung, Kwong-SakWong, Man-HonKung, Hsiang-FuLin, Marie Chia-Mi
- [9] Novel cyano pyridopyrimidines as potent and selective inhibitors of CDK4 and Ark5 kinasesABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243Akula, BalaiahAthuluri, SaikrishnaCosenza, Stephen C.Kumar, VinayReddy, E. PremkumarReddy, M. V. Ramana
- [10] ON 123300, an orally administered novel CDK4/6+ARK5 inhibitor, exhibits potent antitumor activity in vivo: comparative studies with PalbociclibCANCER RESEARCH, 2017, 77Patel, ShraddhaPancholi, PriyaVisal, TanviSamant, AmrutaKansara, DhvanirRajadhyaksha, V. J.Hoffman, Benjamin S.Maniar, ManojSehdev, Vikas